Valeant Pharmaceuticals International (VRX) Reports 2013 First Quarter Financial Results
5/2/2013 7:01:58 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LAVAL, Quebec, May 2, 2013 /PRNewswire/ --
• 2013 First Quarter Total Revenue $1.068 billion; an increase of 25% over the prior year
• 2013 First Quarter Product Sales $1.039 billion; an increase of 38% over the prior year
? Organic growth (same store sales) was 6%, excluding the impact from generics, primarily BenzaClin and Cesamet